C. Fontaine

ORCID: 0000-0003-1760-6458
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Veterinary Medicine and Surgery
  • Reproductive Physiology in Livestock
  • Veterinary Equine Medical Research
  • Sperm and Testicular Function
  • Hormonal and reproductive studies
  • Reproductive Biology and Fertility
  • Animal Behavior and Welfare Studies
  • Bone Tumor Diagnosis and Treatments
  • Virus-based gene therapy research
  • Hepatitis B Virus Studies
  • Lymphoma Diagnosis and Treatment
  • Sexual Differentiation and Disorders
  • Autoimmune and Inflammatory Disorders Research
  • Cytomegalovirus and herpesvirus research
  • Viral gastroenteritis research and epidemiology
  • HIV, Drug Use, Sexual Risk
  • Sexual function and dysfunction studies
  • HIV/AIDS Research and Interventions
  • Hepatitis Viruses Studies and Epidemiology
  • Parvovirus B19 Infection Studies
  • Rabies epidemiology and control
  • Agriculture and Rural Development Research
  • Safe Handling of Antineoplastic Drugs
  • Histiocytic Disorders and Treatments
  • Pericarditis and Cardiac Tamponade

Virbac (France)
2015-2025

Institut Mérieux (France)
2018

Sanofi (France)
2018

National Health Service Wales
2016

Seoul National University
2015

Sorbonne Université
2009-2013

Hôpital Tenon
2009-2013

Université de Lille
2005-2013

Centre Hospitalier de Beauvais
2010

Assistance Publique – Hôpitaux de Paris
2009

Solid organ transplantations (SOT) are performed successfully in selected HIV-infected patients. However, multiple and reciprocal drug-drug interactions observed between antiretroviral (ARV) drugs calcineurin inhibitors (CNIs) through CYP450 metabolization. Raltegravir (RAL), a novel HIV-1 integrase inhibitor, is not substrate of enzymes. We retrospectively reviewed the outcomes 13 transplant patients treated by an RAL + two nucleosidic reverse transcriptase inhibitor (NRTI) regimen, terms...

10.1111/j.1600-6143.2009.02684.x article EN cc-by-nc-nd American Journal of Transplantation 2009-06-10

ABSTRACT Slow‐release GnRH agonist implants containing deslorelin (SRI) are registered for temporary suppression of male fertility. The effect SRI treatment on canine testicular function is well characterised, although the downregulation and subsequent recovery epididymal has not been studied yet. Therefore, twenty‐nine healthy dogs were treated with a 4.7 mg five months. Subsequent to implant removal, groups 4–5 surgically castrated either at removal (week 0) or 2, 4, 6, 10 weeks later....

10.1111/rda.70013 article EN cc-by Reproduction in Domestic Animals 2025-02-01

The absence of fertility problems in male dogs after a single treatment with deslorelin acetate (Suprelorin(®)) is well acknowledged. However, reports on the application bitch and information concerning implant are still limited. In this retrospective study, data induced spontaneous oestruses 39 bitches from 17 breeds, treated implants (4.7 mg Suprelorin(®), Virbac, France), were retrieved to assess post-treatment (ovulation rate, pregnancy rate litter size). Animals grouped according...

10.1111/rda.12616 article EN Reproduction in Domestic Animals 2015-10-08

The objective of this study was to assess duration efficacy, side effects and return fertility following use the 9.4 mg deslorelin implant (Suprelorin 12; Virbac) in cats, test whether efficacy action are influenced by implantation site (interscapular vs periumbilical).

10.1177/1098612x18788157 article EN cc-by Journal of Feline Medicine and Surgery 2018-07-30

This article presents B-mode and color Doppler imaging of the prostate testes in dogs suffering from benign hyperplasia (BPH), receiving deslorelin acetate (SuprelorinTM) or osaterone (YpozaneTM). The study was planned as a controlled clinical trial, were divided into negative control (healthy dogs, n = 10), positive (dogs with BPH, groups, III (n 15), (DA), IV (OA). appearance parenchyma improved all investigated DA group, 60% OA dogs. Prostate volume reduced more quickly (from D14), but...

10.3390/ani10122379 article EN cc-by Animals 2020-12-11

Objectives The purpose of this study was to assess efficacy deslorelin, a gonadotropin-releasing hormone (GnRH) agonist marketed in Europe for the control male dog reproduction, postponement puberty queens. Methods Nine prepubertal queens aged 3–9 months were selected study; their general and reproductive health checked through clinical, haematological, vaginal cytology hormonal tests. Following treatment with 4.7 mg deslorelin implant, each cat received monthly clinical examination blood...

10.1177/1098612x16688406 article EN Journal of Feline Medicine and Surgery 2017-02-14

Deslorelin is currently registered for the induction of temporary infertility in male dogs, cats, ferrets, and also prepubertal female but research has shown its usefulness other conditions requiring chronic treatment. This paper presents six cases dogs chronically treated with deslorelin indications such as benign prostatic hyperplasia, control fertility, abnormal reproductive behavior urinary incontinence. All animals were good health during Treatment duration was 2-9 years. No short-term...

10.3390/ani13020265 article EN cc-by Animals 2023-01-12

Deslorelin implants are widely used in felines. Due to their prolonged duration cat breeders frequently request early implant removal. The interval between deslorelin removal and resumption of ovarian function queens is unknown. aim this study was evaluate the a activity adult queens. Twenty-three were treated with 4.7 mg placed periumbilical area. In 16 completing surgically removed at 3, 6 or 9 months (n = 6, 4 queens, respectively). Queens received GnRH stimulation test as part...

10.1111/rda.14023 article EN Reproduction in Domestic Animals 2021-10-07

This article presents the results of a randomized clinical trial, designed to compare efficacy and therapeutic profiles YpozaneTM (osaterone acetate-OA) or SuprelorinTM (deslorelin acetate-DA) in male dogs with signs benign prostate hyperplasia (BPH). Forty-five intact were used study. The Group I (negative control) included 10 healthy dogs, II (positive confirmed BPH no treatment, whereas III IV consisted treated either DA (15 dogs) OA (10 dogs). response, testosterone estradiol levels,...

10.3390/ani10101936 article EN cc-by Animals 2020-10-21

Benign prostatic hyperplasia (BPH) is one of the most common problems in older male dogs that often has a huge impact on their health and welfare. This article presents comparison between osaterone acetate (Ypozane®; Virbac®)(OA) deslorelin (Suprelorin®; Virbac®)(DA), medications are main therapeutic alternative to castration with BPH. Forty were divided into four groups: I-negative control (five without BPH); II-positive (10 individuals diagnosed III-15 treated DA, IV-10 OA. Semen fractions...

10.3390/ani12121548 article EN cc-by Animals 2022-06-15

This multicenter-controlled, double-masked randomized European study was conduc-ted to confirm both the efficacy and safety of a deslorelin implant in controlling fertility sexual behavior large population tom cats over 12-month period. Among 225 screened individuals, total 205 privately owned indoor intact male cats, aged 3 months age or older, were randomly allocated (n = 154) negative control group 51). After screening visit performed between day (D)-14 D-7, six additional visits...

10.3390/ani13030379 article EN cc-by Animals 2023-01-22

The gonadotropin-releasing hormone (GnRH) stimulation test is a common procedure used to investigate normality of the pituitary-gonadal axis in mammals. There very little information on technique, its efficacy and side effects small animals particular no for male cats. In dogs, such performed by intravenous (IV) administration. With cats, number times animal needs be restrained blood sampling should least possible. purpose this study was assess GnRH tomcats comparing IV with intramuscular...

10.1111/rda.12771 article EN Reproduction in Domestic Animals 2016-11-13

Background: Deslorelin implant use in cats is a medical alternative to surgical sterilization, and due its prolonged efficacy, has shown growing interest the veterinary community. In case of breeding facilities, removal often requested for early restoration testicular function. As anti-Müllerian hormones (AMH) males dependent testosterone secretion, assay may determine steroid secretion. An average 3 weeks been already described tomcats’ function resumption after removal, but information...

10.3390/ani13162552 article EN cc-by Animals 2023-08-08

Abstract Objective Slow-release GnRH agonist implants (SRI) are used for reversible medical downregulation of testicular function in male dogs as an alternative to surgery. The 4.7 mg deslorelin SRI should reduce testosterone after 6–8 weeks and induce castration-like effects 6 months (mon). However, some individual variation is described the field regard onset duration effect. For this reason, we aimed study a larger cohort. Material methods In total 50 intact, healthy (12–48 months, mon;...

10.1055/a-2142-4194 article EN Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere 2023-08-01

Feline calicivirus (FCV) is a common virus, found worldwide, mainly responsible for chronic ulceroproliferative faucitis and periodontitis. This virus has high mutation rate, leading to the presence of numerous FCV strains in field. The objectives this study was evaluate compare efficacy two vaccines (Leucofeligen™ FeLV/RCP Purevax™ RCP FeLV), which differ by their nature (live vs. inactivated) vaccinal strains, against circulating strains. Thirty 9-week-old specific pathogen free (SPF)...

10.1186/s12917-017-1217-y article EN cc-by BMC Veterinary Research 2017-10-10

Deslorelin slow-released implants are registered in Europe for the reversible suppression of fertility male dogs. After administration, a time-limited increase sex hormones concentration and related behavioral problems may be observed. The aim this work was to assess whether cyproterone acetate, synthetic progestogen, can prevent flare-up effect. Eighteen privately-owned entire dogs were enrolled double-blind, placebo-controlled, randomized clinical trial. All subjects received 4.7 mg...

10.3389/fvets.2021.714154 article EN cc-by Frontiers in Veterinary Science 2021-09-29
Coming Soon ...